# Mind Medicine Inc.

Mind Medicine Inc. is a Clinical-stage biopharmaceutical (psychedelic therapeutics) based in New York, United States.

## Overview

- **Organization type:** Clinical-stage biopharmaceutical (psychedelic therapeutics)
- **Headquarters:** New York, United States
- **Region:** North America
- **Address:** New York, NY, United States
- **Founded:** 2019
- **Assets under management:** Undisclosed
- **Website:** https://mindmedicine.com
- **LinkedIn:** https://www.linkedin.com/company/mindmedicine

## Regulatory record

- **Reports private funds:** No

## About

Mind Medicine Inc. was established as a clinical-stage biopharmaceutical company, publicly traded on the Nasdaq under the ticker MNMD. The firm focuses on developing psychedelic-derived compounds, such as MM-120 (a synthetic form of LSD), for psychiatric disorders, alongside a digital therapeutic pipeline that leverages AI to personalize mental health care. Founders and early leadership included a blend of neuroscience researchers and technology entrepreneurs, though current named operators are not publicly listed. The firm's strategy spans drug development, digital assessment platforms, and potential direct-to-consumer applications. It has disclosed Phase 2b trial results for MM-120 in generalized anxiety disorder (per the firm, 2024) and maintains a pipeline addressing major depressive disorder and post-traumatic stress disorder. The digital arm employs machine learning to analyze patient data, targeting precision psychiatry. Geographic focus is primarily North American, with clinical trial sites across the United States and Europe. Scale remains early-stage: the firm has no disclosed AUM or assets under management, as it is a development-stage enterprise rather than an investment vehicle. It employs a small research and operational team based in New York. No recent operational events (past 24 months) beyond the Phase 2b data release have been publicly identified. The structural differentiator is Mind Medicine's hybrid architecture: it is a public company pursuing FDA-regulated drug approval while simultaneously developing proprietary software-based biomarkers and digital therapeutics — an unusual mandate that bridges regulated pharma and health-tech innovation, with governance through a public board and standard SEC filings.

## Sectors

- Digital Health
- AI/ML

## Questions

### What is Mind Medicine Inc.'s core therapeutic focus?

Mind Medicine Inc. targets psychiatric disorders such as generalized anxiety disorder, major depressive disorder, and post-traumatic stress disorder using psychedelic-inspired compounds and digital therapeutics. Its lead candidate, MM-120, is a synthetic LSD formulation that completed Phase 2b trials for generalized anxiety disorder in 2024 (per the firm).

### What is the relationship between Mind Medicine Inc.'s drug development and its digital therapeutics?

The firm integrates drug development with proprietary digital platforms that use AI to analyze patient biomarkers and personalize treatment. This dual approach aims to create a full-stack mental health solution, combining pharmacological intervention with software-based monitoring and therapy, though the digital arm is still early-stage.

### Where does Mind Medicine Inc. operate?

The firm is headquartered in New York, United States. Its clinical trials have been conducted at sites across the US and Europe (per the firm's public filings). Additional offices are not publicly disclosed.

### What is known about Mind Medicine Inc.'s leadership?

The firm's leadership includes a CEO and a scientific advisory board, but no named principals are publicly listed in the available Altss research record. The company files with the SEC, and public filings can be consulted for current officers and directors.

### How is Mind Medicine Inc. funded?

Mind Medicine Inc. is publicly traded on the Nasdaq, raising capital through equity offerings and, historically, through special purpose acquisition company (SPAC) merger. It does not manage third-party capital or maintain AUM, as it is a development-stage company.

## Related profiles

- [Magec Tech](https://altss.com/profile/magec-tech)
- [Federal Signal Corporation](https://altss.com/profile/federal-signal-corporation)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/mind-medicine-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology